个人科研网厅 | | 帮助
高级检索
当前位置： 首页 > 详情页

Surufatinib (S) for patients (Pts) with advanced pancreatic neuroendocrine tumours (SANET-p): A randomized, double-blind, placebo (P)-controlled phase III trial (NCT02589821)

| 认领 | 导出 | |

文献详情

资源类型：
WOS体系：

收录情况： ◇ SCIE ◇ CPCI(ISTP)

作者：
Xu, J.[1] * ; Shen, L.[2] ; Bai, C.[3] ; Li, J.[2] ; Zhou, Z.[4] ; Yu, X.[5] ; Li, Z.[6] ; Li, E.[7] ; Yuan, X.[8] ; Chi, Y.[9,10] ; Yin, Y.[11] ; Lou, W.[12] ; Xu, N.[13] ; Bai, Y.[14] ; Zhang, T.[15] ; Xiu, D.[16] ; Wang, X.[17] ; Li, J.[2] ; Fan, S. ; Su, W.[18] ;
单位： [1]Gen Hosp Peoples Liberat Army, Dept Gastrointestinal Oncol, Med Ctr 5, Beijing, Peoples R China [2]Peking Univ Canc Hosp & Inst, Dept GI Oncol, Beijing, Peoples R China [3]Peking Union Med Coll Hosp, Dept Oncol, Beijing, Peoples R China [4]Sun Yat Sen Univ, Collaborat Innovat Ctr Canc Med, State Key Lab Oncol South China, Dept Gastr Surg,Canc Ctr, Guangzhou, Guangdong, Peoples R China [5]Fudan Univ, Shanghai Canc Ctr, Dept Pancreat & Hepatobiliary Surg, Shanghai, Peoples R China [6]Sichuan Univ, West China Hosp, Dept Abdominal Oncol, Chengdu, Sichuan, Peoples R China [7]Xi An Jiao Tong Univ, Affiliated Hosp 1, Dept Med Oncol, Xian, Shaanxi, Peoples R China [8]Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Dept Oncol, Wuhan, Hubei, Peoples R China [9]Chinese Acad Med Sci, Canc Hosp, Natl Canc Ctr, Beijing, Peoples R China [10]Peking Union Med Coll, Beijing, Peoples R China [11]Nanjing Med Univ, Affiliated Hosp 1, Dept Oncol, Nanjing, Jiangsu, Peoples R China [12]Fudan Univ, Zhongshan Hosp, Dept Gen Surg, Shanghai, Peoples R China [13]Zhejiang Univ, Affiliated Hosp 1, Dept Med Oncol, Hangzhou, Zhejiang, Peoples R China [14]Harbin Med Univ Canc Hosp, Dept Gastrointestinal Oncol, Harbin, Peoples R China [15]Huazhong Univ Sci & Technol, Tongji Med Coll, Union Hosp, Canc Ctr, Wuhan, Hubei, Peoples R China [16]Peking Univ, Hosp 3, Dept Gen Surg, Beijing, Peoples R China [17]Shandong Univ, Qilu Hosp, Dept Med Oncol, Jinan, Peoples R China [18]Hutchison MediPharma Ltd, Clin Dept & Regulatory Affairs, Shanghai, Peoples R China
出处：
DOI： 10.1016/j.annonc.2020.08.1369
ISSN：
基金：
Hutchison MediPharma Limited
语种：
外文
被引次数：
WOS：
中科院(CAS)分区：
出版当年[2019]版：
大类 | 1 区 医学
小类 | 1 区 肿瘤学
最新[2025]版：
大类 | 1 区 医学
小类 | 1 区 肿瘤学
JCR分区：
出版当年[2018]版：
Q1 ONCOLOGY
最新[2023]版：
Q1 ONCOLOGY

影响因子： 最新[2023版] 最新五年平均 出版当年[2018版] 出版当年五年平均 出版前一年[2017版] 出版后一年[2019版]

第一作者：
第一作者单位： [1]Gen Hosp Peoples Liberat Army, Dept Gastrointestinal Oncol, Med Ctr 5, Beijing, Peoples R China
推荐引用方式(GB/T 7714)：
Xu J.,Shen L.,Bai C.,et al.Surufatinib (S) for patients (Pts) with advanced pancreatic neuroendocrine tumours (SANET-p): A randomized, double-blind, placebo (P)-controlled phase III trial (NCT02589821)[J].ANNALS OF ONCOLOGY.2020,31:S770-S770.doi:10.1016/j.annonc.2020.08.1369.
APA：
Xu, J.,Shen, L.,Bai, C.,Li, J.,Zhou, Z....&Su, W..(2020).Surufatinib (S) for patients (Pts) with advanced pancreatic neuroendocrine tumours (SANET-p): A randomized, double-blind, placebo (P)-controlled phase III trial (NCT02589821).ANNALS OF ONCOLOGY,31,
MLA：
Xu, J.,et al."Surufatinib (S) for patients (Pts) with advanced pancreatic neuroendocrine tumours (SANET-p): A randomized, double-blind, placebo (P)-controlled phase III trial (NCT02589821)".ANNALS OF ONCOLOGY 31.(2020):S770-S770

资源点击量：451 今日访问量：0 总访问量：425 更新日期：2025-05-01 建议使用谷歌、火狐浏览器 常见问题

版权所有：重庆聚合科技有限公司 渝ICP备12007440号-3 地址：重庆市两江新区泰山大道西段8号坤恩国际商务中心16层（401121）